Hostname: page-component-586b7cd67f-t7czq Total loading time: 0 Render date: 2024-11-22T19:56:42.075Z Has data issue: false hasContentIssue false

A Comparative Trial of Mandrax and Dichloralphenazone

Published online by Cambridge University Press:  29 January 2018

Ijaz Haider*
Affiliation:
Department of Child and Family Psychiatry, Stratheden Hospital, Playfield House, Cupar, Fife, and Severalls Hospital, Colchester, Essex. Present address: Edinburgh University Department of Psychiatry, Royal Edinburgh Hospital, Morningside Park, Edinburgh 10

Extract

Mandrax is a combination of methaqualone 250 mg. and diphenhydramine 25 mg. Burke and Mahadevan (1966) have found it to be as potent in this dosage as 200 mg. of butobarbitone.

Type
Research Article
Copyright
Copyright © Royal College of Psychiatrists, 1968 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Boissier, J.-R., Dumont, C., and Malen, C. (1958). “Pharmacological study of a new hypnotic: 2-methyl 3-orthotolyl 4-quinazolone” Therapie, xiii, 3045.Google Scholar
Burke, H., and Mahadevan, M. (1966). “Preliminary clinical trial of a new hypnotic combination—Mandrax” Clinical Trials Journal, 3, 417419.Google Scholar
Gujral, M. L., Kohli, R. P., and Saxena, P. N. (1955). “A preliminary report on some new synthetic hypnotics” Medicine, 2, 16.Google Scholar
Parsons, T. W., and Thomson, T. J. (1961). “Methaqualone as a hypnotic” Brit. med. J., i, 171173.Google Scholar
Weaver, L. C., Jones, W. R., Kerley, T. L. (1963). “Some central nervous system depressant properties of 2-methyl-3-o-tolyl-4 (3H)- quinazolinone (TR 495) (i)” Arch. int. Pharmacodyn., 143, No. 1–2, 119126.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.